Lexeo Therapeutics Aktie News

Lexeo Therapeutics, Inc. has surged after FDA alignment on a pivotal trial for LX2006, targeting Friedreich's ataxia cardiomyopathy. LX2006 shows promising efficacy and safety, with significant LVMI reduction and increased frataxin expression, positioning LXEO as a potential best-in-class therapy. LXEO is well-funded into 2028 after recent financings, and analysts remain bullish, forecasting st...

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal st...

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, befo...

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public offering and concurrent private placement for gross proceeds to Lexeo of approximately $135 million, before deducting underwriting discounts ...

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has commenced an underwritten public offering and concurrent private placement of shares of its common stock and, in lieu of common stock to certain investors, pr...

Lexeo Therapeutics received positive FDA feedback, enabling a faster path to Accelerated Approval for LX2006 in FA cardiomyopathy. Pooled phase 1/2 interim data for LX2006 show LVMI improvements well above FDA thresholds at 6 and 12 months, supporting efficacy. LXEO maintains strong financials, with cash reserves expected to fund operations into 2028 after a recent $80 million private placement.

Lexeo Therapeutics, Inc. - Special Call Company Participants Louis Tamayo - CFO & Principal Accounting Officer R. Townsend - CEO & Director Sandi Tai - Chief Development Officer Eric Adler - Chief Medical Officer & Head of Research Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Brian Skorney - Robert W.

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich ataxia Participants with abnormal left ventricula...